Effect of Cilostazol to a patient who merges lumbar spinal canal stenosis and arteriosclerosis obliterans.

Effect of Cilostazol to a patient who merges lumbar spinal canal stenosis and arteriosclerosis obliterans. - Effect of Cilostazol to a patient who merges lumbar spinal canal stenosis and arteriosclerosis obliterans.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009997

Enrollment

Registered

2013-02-11

Start date

2013-02-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar spinal canal stenosis arteriosclerosis obliterans

Interventions

limaprost cilostazol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, The patient diagnosed as spinal canal stenosis by the diagnostic support tool and magnetic resonance image. 2, The patient diagnosed as arteriosclerosis obliterans by ABI (<1.0) or TPI (<=0.6) The patient who was able to acquire the approve by letter to the work preinitiation

Exclusion criteria

Exclusion criteria: 1, The contraindication patient of a cilostazol . 2, The patient who cannot understand the main point of this research 3, The patient more than 3 degree of Fontaine classification

Design outcomes

Primary

Measure	Time frame
Visual Analog Scale Japanese Orthopaedic Association Score Japanese Orthopaedic Association Back Pain Evaluation Questionnaire Walking Impairment Questionnaire	—

Countries

Japan

Contacts

Public ContactHideyuki Arima

Hamamatsu University School of Medicine Department of orthopedic surgery

arihidee@yahoo.co.jp053-435-2299

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026